Product Description
Chenodeoxycholic acid (chenodiol) is a primary bile acid, synthesized in the liver and present in high concentrations in bile that is used therapeutically to dissolve cholesterol gallstones. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK547907/)
Mechanisms of Action: FXR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Chile | Croatia | Czech | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Latvia | Lithuania | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Fujimoto
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil, Jordan, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Xanthomatosis, Cerebrotendinous
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RESTORE | P3 |
Completed |
Xanthomatosis, Cerebrotendinous |
2023-07-13 |
|
| 250mg Chenodeoxycholic Acid | P1 |
Completed |
Xanthomatosis, Cerebrotendinous |
2022-07-18 |